AR059432A1 - Anticuerpos anti-fgf19 y metodos que usan estos - Google Patents

Anticuerpos anti-fgf19 y metodos que usan estos

Info

Publication number
AR059432A1
AR059432A1 ARP070100563A ARP070100563A AR059432A1 AR 059432 A1 AR059432 A1 AR 059432A1 AR P070100563 A ARP070100563 A AR P070100563A AR P070100563 A ARP070100563 A AR P070100563A AR 059432 A1 AR059432 A1 AR 059432A1
Authority
AR
Argentina
Prior art keywords
sequence
hvr
methods
fgf19
antibodies
Prior art date
Application number
ARP070100563A
Other languages
English (en)
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR059432A1 publication Critical patent/AR059432A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP070100563A 2006-02-10 2007-02-09 Anticuerpos anti-fgf19 y metodos que usan estos AR059432A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77231006P 2006-02-10 2006-02-10
US78060806P 2006-03-09 2006-03-09
US88586607P 2007-01-19 2007-01-19

Publications (1)

Publication Number Publication Date
AR059432A1 true AR059432A1 (es) 2008-04-09

Family

ID=38723925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100563A AR059432A1 (es) 2006-02-10 2007-02-09 Anticuerpos anti-fgf19 y metodos que usan estos

Country Status (10)

Country Link
US (4) US7678373B2 (enExample)
EP (1) EP1989230B1 (enExample)
JP (1) JP5209505B2 (enExample)
AR (1) AR059432A1 (enExample)
AU (1) AU2007254005B2 (enExample)
CA (1) CA2637988A1 (enExample)
ES (1) ES2582652T3 (enExample)
NZ (1) NZ569957A (enExample)
TW (1) TWI388568B (enExample)
WO (1) WO2007136893A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2614039C (en) 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
AU2007254005B2 (en) 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same
JP5328018B2 (ja) * 2006-06-05 2013-10-30 国立大学法人広島大学 抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
NO2550972T3 (enExample) * 2007-04-02 2018-07-21
ES2622107T3 (es) * 2007-08-03 2017-07-05 Genentech, Inc. Antagonistas anti-FGF19 humanizados y métodos de uso de los mismos
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
US20090226459A1 (en) * 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
US20110124574A1 (en) * 2008-04-30 2011-05-26 Tommy Andersson Restoration of estrogen receptor-(alpha) activity
CA2727278A1 (en) * 2008-06-16 2010-01-21 Immunogen, Inc. Novel synergistic effects
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4
MX368790B (es) * 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
ES2600631T3 (es) 2009-11-13 2017-02-10 Five Prime Therapeutics, Inc. Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
JP4881428B2 (ja) * 2009-12-25 2012-02-22 株式会社東芝 電子機器
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CN108220297A (zh) 2011-03-09 2018-06-29 细胞信号科技公司 用于生成单克隆抗体的方法和试剂
WO2012177481A2 (en) * 2011-06-24 2012-12-27 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
TW201326201A (zh) 2011-11-14 2013-07-01 Five Prime Therapeutics Inc 治療癌症之方法
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
JP2015506944A (ja) * 2012-01-18 2015-03-05 ジェネンテック， インコーポレイテッド Ｆｇｆ１９修飾薬を使用する方法
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
BR112015010740B1 (pt) 2012-11-13 2024-01-30 Biontech Ag Agentes para tratamento de doenças cancerosas expressando claudina
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
JP6673847B2 (ja) * 2013-12-20 2020-03-25 アンギオビオメト ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌治療に使用するためのアドレノメデュリンバインダー
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
JP6585167B2 (ja) 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
WO2016065106A1 (en) * 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
AU2016238436A1 (en) 2015-03-25 2017-08-17 Novartis Ag Formylated N-heterocyclic derivatives as FGFR4 inhibitors
EP3414267B1 (en) 2016-02-10 2023-12-27 BioInvent International AB Combination of human anti-fgfr4 antibody and sorafenib
US10813933B2 (en) * 2016-05-17 2020-10-27 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
ES2934341T3 (es) 2016-11-02 2023-02-21 Novartis Ag Combinaciones de inhibidores de FGFR4 y secuestrantes de ácidos biliares
US20190218285A1 (en) * 2018-01-18 2019-07-18 Molecular Cloning Laboratories (MCLAB) LLC Long-Acting Therapeutic Fusion Proteins
CN109251983B (zh) * 2018-08-15 2022-03-25 深圳市罗湖区人民医院 Frs2基因的拷贝数扩增及其应用、检测拷贝数扩增的特异性引物对
CN113710701B (zh) * 2019-02-02 2025-02-28 华辉安健（北京）生物科技有限公司 抗fgf19抗体
ES2934984T3 (es) * 2020-02-13 2023-02-28 Orano Med Procedimiento para la modificación específica del sitio de un anticuerpo
CN116726005A (zh) * 2022-03-03 2023-09-12 上海市第六人民医院 一种治疗运动损伤的药物及筛选方法和应用
IL316411A (en) 2022-05-19 2024-12-01 Tyra Biosciences Inc Therapies with PPAR agonists and FGFR4 inhibitors
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US20020012961A1 (en) * 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
US20020042367A1 (en) * 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20040126852A1 (en) * 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
AU733222B2 (en) 1997-11-25 2001-05-10 Genentech Inc. Fibroblast growth factor-19
US20050026832A1 (en) * 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20020155543A1 (en) * 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
CA2384089A1 (en) 1999-09-08 2001-03-15 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
MXPA02009224A (es) 2000-03-22 2003-03-12 Amgen Inc Moleculas similares a receptor de factor de crecimiento de fibroblastos y usos de las mismas.
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
JP2005518782A (ja) 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
JP2005522999A (ja) 2002-01-31 2005-08-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 癌を処置するための方法および組成物
CA2486252C (en) * 2002-06-07 2012-07-24 Genentech, Inc. Methods for screening for agents that modulate hepatocellular carcinoma development
US20050198642A1 (en) * 2004-03-04 2005-09-08 International Business Machines Corporation Mechanism for assigning home nodes to newly created threads
US7837626B2 (en) * 2005-08-05 2010-11-23 Siemens Medical Solutions Usa, Inc. Contrast agent manipulation with medical ultrasound imaging
AU2007254005B2 (en) 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same

Also Published As

Publication number Publication date
US20110086032A1 (en) 2011-04-14
US20070248604A1 (en) 2007-10-25
TW200808827A (en) 2008-02-16
ES2582652T3 (es) 2016-09-14
US20120128675A1 (en) 2012-05-24
US7846691B2 (en) 2010-12-07
AU2007254005A1 (en) 2007-11-29
AU2007254005B2 (en) 2012-11-29
US8241633B2 (en) 2012-08-14
HK1120273A1 (zh) 2009-03-27
WO2007136893A2 (en) 2007-11-29
TWI388568B (zh) 2013-03-11
EP1989230B1 (en) 2016-06-01
CA2637988A1 (en) 2007-11-29
JP2009525764A (ja) 2009-07-16
EP1989230A2 (en) 2008-11-12
WO2007136893A3 (en) 2008-05-15
US20100129381A1 (en) 2010-05-27
JP5209505B2 (ja) 2013-06-12
NZ569957A (en) 2012-03-30
US7678373B2 (en) 2010-03-16
US8293241B2 (en) 2012-10-23

Similar Documents

Publication Publication Date Title
AR059432A1 (es) Anticuerpos anti-fgf19 y metodos que usan estos
CO6220835A2 (es) Anticuerpos anti-robo4 y sus usos
RU2011134500A (ru) Антитела и иммуноконъюгаты и их применения
AR067544A1 (es) Anticuerpos anti- cd79b e inmunoconjugados y metodos de uso de los mismos
AR067543A1 (es) Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
CO6331344A2 (es) Anticuerpos aislados que unen a vegf, composiciones farmaceuticas que los comprenden y un portador farmaceuticamente aceptable y usos de los mismos
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
AR076030A1 (es) Anticuerpos anti-fcrh5 (fc-receptor homologo) e inmunoconjugados y metodos de uso
MX356367B (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CU24663B1 (es) Dominio de unión a antígeno anti-trbc1, receptor de antígeno quimérico, anticuerpo y acoplador biespecífico de células t que comprenden el mismo
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
AR076029A1 (es) Anticuerpos anti- fcrh5 (receptor de translocacion asociado a la superfamilia de inmunoglobulina) e inmunoconjugados y metodos de uso
AR082916A1 (es) Moleculas de union a 4-1bb
HRP20171190T1 (hr) Protutijelo protiv beta-amiloida i njegove upotrebe
PE20121023A1 (es) Anticuerpos e inmunoconjugados
ES2628108T3 (es) Anticuerpos multiespecíficos
AR058932A1 (es) Anticuerpos anti-ephb4 y metodos que usan estos
AR076662A1 (es) Anticuerpos anti-egfl7 humanizados y metodos de uso de los mismos
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
RU2014108047A (ru) Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы
NZ602040A (en) Anti-lrp6 antibodies
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use
JP2011173884A5 (enExample)

Legal Events

Date Code Title Description
FC Refusal